Nanobiotix (NASDAQ:NBTX) Shares Gap Down - What's Next?

Key Points

• Nanobiotix gapped down premarket, opening at $31.93 after a prior close of $35.12 (last trade $31.93) with a 50‑day SMA of $31.69 and 200‑day SMA of $25.25.
• Analyst sentiment is mixed but overall a “Moderate Buy” consensus with a consensus target of $26.67; four analysts rate it Buy, one Hold and one Sell, while recent target revisions include UBS to $30 and Guggenheim to $36.
• Nano‑biotech company is clinical‑stage with lead product NBTXR3 (a hafnium‑oxide nanoparticle radioenhancer) that has a CE Mark for soft tissue sarcoma, and institutional/hedge fund ownership is ~38.8% with several funds recently adding positions.

Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX - Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $35.12, but opened at $31.93. Nanobiotix shares last traded at $31.9330, with a volume of 28,232 shares changing hands.

Wall Street Analyst Weigh In

NBTX has been the topic of several research reports. UBS Group upped their price target on Nanobiotix from $3.50 to $30.00 and gave the company a "neutral" rating in a report on Friday. Guggenheim upped their price target on Nanobiotix from $26.00 to $36.00 and gave the company a "buy" rating in a report on Thursday, April 2nd. Weiss Ratings reissued a "sell (d-)" rating on shares of Nanobiotix in a research note on Tuesday, April 21st. Finally, TD Cowen reissued a "buy" rating on shares of Nanobiotix in a research note on Thursday, March 12th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $26.67.

Nanobiotix Stock Performance

The firm's 50 day simple moving average is $31.69 and its 200-day simple moving average is $25.25.

Nanobiotix (NASDAQ:NBTX - Get Free Report) last announced its earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share (EPS) for the quarter. The business had revenue of $3.42 million for the quarter. Equities research analysts anticipate that Nanobiotix S.A. - Sponsored ADR will post 0.53 earnings per share for the current year.

Hedge Funds Weigh In On Nanobiotix

A number of hedge funds have recently modified their holdings of NBTX. Millennium Management LLC acquired a new position in shares of Nanobiotix in the fourth quarter worth $390,000. Marshall Wace LLP acquired a new position in shares of Nanobiotix in the fourth quarter worth $220,000. Optiver Holding B.V. acquired a new position in shares of Nanobiotix in the third quarter worth $101,000. Finally, Royal Bank of Canada increased its stake in shares of Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company's stock worth $61,000 after acquiring an additional 2,500 shares during the last quarter. 38.81% of the stock is owned by institutional investors and hedge funds.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company's lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.